NCT02601950 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 32
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 62
- group Id
- BG005
- value
- 69
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 267
- units
- Participants
- groups
- description
- Participants with rhabdoid tumors (MRT, RTK, ATRT, and selected tumors with rhabdoid features, including SCCOHT, also known as MRTO) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG000
- title
- Rhabdoid Tumors: Cohort 1
- description
- Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG001
- title
- Synovial Sarcoma: Cohort 2
- description
- Participants with other INI-1-negative tumors or any solid tumor with EZH2 GOF mutation, including EMPNST, EMC, myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG002
- title
- Other INI1-negative: Cohort 3
- description
- Participants with RMC received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG003
- title
- RMC: Cohort 4
- description
- Participants with ES received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG004
- title
- ES: Cohort 5
- description
- Participants with ES undergoing optional tumour biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG005
- title
- ES Paired Biopsy: Cohort 6
- description
- Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG006
- title
- Chordoma: Cohort 7
- description
- Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG007
- title
- ES 1600 mg: Cohort 8
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 16.31
- value
- 37.9
- group Id
- BG001
- spread
- 9.54
- value
- 38.8
- group Id
- BG002
- spread
- 16.94
- value
- 46.9
- group Id
- BG003
- spread
- 10.71
- value
- 30.7
- group Id
- BG004
- spread
- 15.08
- value
- 37.0
- group Id
- BG005
- spread
- 14.00
- value
- 41.3
- group Id
- BG006
- spread
- 17.49
- value
- 38.9
- group Id
- BG007
- spread
- 15.74
- value
- 40.9
- group Id
- BG008
- spread
- 14.89
- value
- 39.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 23
- group Id
- BG005
- value
- 26
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 113
- title
- Female
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 39
- group Id
- BG005
- value
- 43
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 154
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 21
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 53
- group Id
- BG005
- value
- 55
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 231
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 22
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 26
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 47
- group Id
- BG005
- value
- 54
- group Id
- BG006
- value
- 16
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 200
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 17
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Intent-to-treat (ITT) population included all participants who received at least 1 dose of tazemetostat.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 32
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 62
- group Id
- BG005
- value
- 69
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 267
- units
- Participants
- groups
- description
- Participants with rhabdoid tumors (MRT, RTK, ATRT, and selected tumors with rhabdoid features, including SCCOHT, also known as MRTO) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG000
- title
- Rhabdoid Tumors: Cohort 1
- description
- Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG001
- title
- Synovial Sarcoma: Cohort 2
- description
- Participants with other INI-1-negative tumors or any solid tumor with EZH2 GOF mutation, including EMPNST, EMC, myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG002
- title
- Other INI1-negative: Cohort 3
- description
- Participants with RMC received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG003
- title
- RMC: Cohort 4
- description
- Participants with ES received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG004
- title
- ES: Cohort 5
- description
- Participants with ES undergoing optional tumour biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG005
- title
- ES Paired Biopsy: Cohort 6
- description
- Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG006
- title
- Chordoma: Cohort 7
- description
- Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.
- id
- BG007
- title
- ES 1600 mg: Cohort 8
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 16.31
- value
- 37.9
- group Id
- BG001
- spread
- 9.54
- value
- 38.8
- group Id
- BG002
- spread
- 16.94
- value
- 46.9
- group Id
- BG003
- spread
- 10.71
- value
- 30.7
- group Id
- BG004
- spread
- 15.08
- value
- 37.0
- group Id
- BG005
- spread
- 14.00
- value
- 41.3
- group Id
- BG006
- spread
- 17.49
- value
- 38.9
- group Id
- BG007
- spread
- 15.74
- value
- 40.9
- group Id
- BG008
- spread
- 14.89
- value
- 39.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 23
- group Id
- BG005
- value
- 26
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 113
- title
- Female
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 39
- group Id
- BG005
- value
- 43
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 154
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 21
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 53
- group Id
- BG005
- value
- 55
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 231
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 22
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 26
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 47
- group Id
- BG005
- value
- 54
- group Id
- BG006
- value
- 16
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 200
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 17
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Intent-to-treat (ITT) population included all participants who received at least 1 dose of tazemetostat.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle